Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotech firm, has announced that its CEO, Dr. James Helliwell, will present in a webinar on the increasing prevalence of osteoarthritis, a condition affecting over 30 million people in the U.S. The webinar, titled ‘Exploring the Rapid Rise of Osteoarthritis,’ is open for public registration and will include a Q&A session. Eupraxia is leveraging its proprietary DiffuSphere™ technology to develop extended-release products aimed at addressing areas with high unmet medical needs, having recently achieved positive results in a Phase 2b trial for knee pain treatment.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
